275 results on '"Chung, Chuhan"'
Search Results
2. Acetyl-CoA carboxylase inhibitor increases LDL-apoB production rate in NASH with cirrhosis: prevention by fenofibrate
3. Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis
4. PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitis
5. IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH
6. Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat
7. Multi stain graph fusion for multimodal integration in pathology
8. Elevated de novo lipogenesis, slow liver triglyceride turnover, and clinical correlations in nonalcoholic steatohepatitis patients
9. A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation
10. A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH.
11. A Fibrosis‐Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing Cholangitis
12. Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSC
13. Integration of deep learning-based histopathology and transcriptomics reveals key genes associated with fibrogenesis in patients with advanced NASH
14. Methylation signatures in peripheral blood are associated with marked age acceleration and disease progression in patients with primary sclerosing cholangitis.
15. Early Deregulation of Cholangiocyte NR0B2 During Primary Sclerosing Cholangitis
16. THU-219 Inhibition of HSD17B13 by INI-822 phenocopies the hepatic lipidomic profile of humans with the protective allele
17. SAT-233 Clinical pharmacokinetics of INI-822, a small molecule inhibitor of HSD17B13
18. The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS‐9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis
19. Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis
20. GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease
21. DNA methylation signatures reflect aging in patients with nonalcoholic steatohepatitis
22. Inter- and Intra-individual Variation, and Limited Prognostic Utility, of Serum Alkaline Phosphatase in a Trial of Patients With Primary Sclerosing Cholangitis
23. Development of a target engagement biomarker for HSD17B13: preclinical pharmacodynamic studies of small molecule inhibition of HSD17B13 by INI-822
24. Analytical and clinical validation of AIM-NASH: a digital pathology tool for artificial intelligence-based measurement of non-alcoholic steatohepatitis histology
25. AI-based histologic scoring enables automated and reproducible assessment of enrollment criteria and endpoints in NASH clinical trials
26. AI-based automation of enrollment criteria and endpoint assessment in clinical trials in liver diseases
27. Pigment Epithelium-Derived Factor (PEDF) Inhibits Wnt/β-catenin Signaling in the Liver
28. Hepatic Deletion of X-Box Binding Protein 1 in FXR Null Mice Leads to Enhanced Liver Injury
29. En masse organoid phenotyping informs metabolic-associated genetic susceptibility to NASH
30. Liver Stiffness Thresholds to Predict Disease Progression and Clinical Outcomes in Bridging Fibrosis and Cirrhosis
31. Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis
32. IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH
33. Safety and efficacy of the farnesoid X receptor (FXR) agonist cilofexor in a proof-of-concept study in patients with compensated cirrhosis due to primary sclerosing cholangitis (PSC)
34. Associations between novel serum biomarkers chitinase-2-like protein (YKL-40), type IV collagen, and thrombospondin-2 (TSP-2) with fibrosis stage and clinical outcomes in patients with primary sclerosing cholangitis (PSC)
35. The MRI and AST (MAST) score is correlated with noninvasive and histologic markers of fibrosis in patients with advanced fibrosis due to NASH
36. Machine learning-enabled continuous scoring of histologic features facilitates prediction of clinical disease progression in patients with non-alcoholic steatohepatitis
37. Pigment Epithelium-derived Factor is an Angiogenesis and Lipid Regulator that Activates Peroxisome Proliferator-activated Receptor α
38. Multi stain graph fusion for multimodal integration in pathology
39. Reply
40. Absence of Nogo-B (Reticulon 4B) Facilitates Hepatic Stellate Cell Apoptosis and Diminishes Hepatic Fibrosis in Mice
41. Reply
42. Hepatic Deletion of X-box Binding Protein 1 in Farnesoid X Receptor Null Mice Leads to Enhanced Liver Injury
43. Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis
44. The vacuolar-ATPase modulates matrix metalloproteinase isoforms in human pancreatic cancer
45. Pigment Epithelium-Derived Factor Regulates Early Pancreatic Fibrotic Responses and Suppresses the Profibrotic Cytokine Thrombospondin-1
46. A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis
47. Insulin resistance is associated with elevated serum pigment epithelium–derived factor (PEDF) levels in morbidly obese patients
48. Pigment Epithelium-Derived Factor (PEDF) Suppresses IL-1β-Mediated c-Jun N-Terminal Kinase (JNK) Activation to Improve Hepatocyte Insulin Signaling
49. WED-401 - Development of a target engagement biomarker for HSD17B13: preclinical pharmacodynamic studies of small molecule inhibition of HSD17B13 by INI-822
50. Cerebral Blood Flow in Acute Liver Failure: A Finding in Search of a Mechanism
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.